| Drug Name |
Tolvaptan |
| Drug ID |
BADD_D02246 |
| Description |
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. |
| Indications and Usage |
Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
C03XA01 |
| DrugBank ID |
DB06212
|
| KEGG ID |
D01213
|
| MeSH ID |
D000077602
|
| PubChem ID |
216237
|
| TTD Drug ID |
D03KZM
|
| NDC Product Code |
46602-0027; 46602-0028; 14501-0066; 67877-637; 60505-4705; 49884-768; 59148-020; 31722-869; 46602-0031; 59148-083; 60505-4704; 49884-770; 59148-082; 59148-089; 14501-0085; 46602-0029; 59148-087; 59148-079; 65977-0100; 60862-008; 46602-0030; 59148-021; 59148-080; 57884-0027; 59148-088; 67877-636 |
| Synonyms |
Tolvaptan | 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine | Samsca | OPC 41061 | OPC-41061 | OPC41061 |
